The stunning success of Novo Nordisk A/S's semaglutide has filled the coffers of the controlling shareholder of the Danish drugmaker which is dipping into its mountain of cash to acquire contract manufacturer Catalent, Inc for $16.5bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?